Literature DB >> 23137515

Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells.

Magdalene Nakou1, Eva D Papadimitraki, Antonios Fanouriakis, George K Bertsias, Christianna Choulaki, Nektaria Goulidaki, Prodromos Sidiropoulos, Dimitrios T Boumpas.   

Abstract

OBJECTIVES: Excessive interleukin- (IL-) 21 production by T cells has been implicated in the pathogenesis of systemic lupus erythematosus (SLE). We explored the expression and function of IL-21 in human SLE.
METHODS: IL-21 and IL-21 receptor (IL-21R) expression was assessed by real-time PCR and flow cytometry in peripheral blood mononuclear cells (PBMCs) of SLE patients and healthy controls. PBMCs, purified CD19+CD27- naïve and CD19+CD27+ memory B cells were stimulated with IL-21 and CpG-ODN2006 (TLR-9 agonist) to examine generation of memory and plasma (CD19+CD38highIgD-) B cells. Apoptosis was assessed by 7AAD staining.
RESULTS: Active SLE patients had 4-fold higher IL-21 mRNA and increased levels of intracellular IL-21 in peripheral blood CD4+ T cells (mean±SD fluorescence intensity, 1.7±0.1 in active versus 0.9±0.3 in inactive SLE and controls, p=0.035). IL-21R mRNA was comparable between SLE and healthy controls. Stimulation of PBMCs with IL-21 increased the proportion of memory and plasma cells; addition of CpG-ODN2006 enhanced these effects. Both naïve and memory B cells responded to IL-21/TLR-9 by increased generation of memory and plasma B cells, respectively; an anti-apoptotic effect was observed. In active SLE, PBMCs stimulation with IL-21 and/or CpG-ODN increased memory and plasma B cells, comparable to healthy controls. Addition of IL-21 to lupus autologous mixed lymphocyte cultures induced significant IgG production, and treatment with IL-21R.Fc to block IL-21/IL-21R interaction reduced the proportion of plasma cells.
CONCLUSIONS: Increased IL-21 may synergise with TLR-9 signalling and contributes to generation of plasma cells in active SLE patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137515

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  37 in total

1.  Interleukin-21, a potential diagnostic and therapeutic target for systemic lupus erythematosus.

Authors:  Yong He; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Rheumatol Int       Date:  2013-09-08       Impact factor: 2.631

Review 2.  Ten developments in the use of biologicals for systemic lupus erythematosus.

Authors:  Daniel J Wallace
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

3.  Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice.

Authors:  Xiaobin Tang; Bo Zhang; Justin A Jarrell; Jordan V Price; Hongjie Dai; Paul J Utz; Samuel Strober
Journal:  J Autoimmun       Date:  2014-02-07       Impact factor: 7.094

4.  Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.

Authors:  Yumi Nakayama; Jolanta Kosek; Lori Capone; Eun Mi Hur; Peter H Schafer; Garth E Ringheim
Journal:  J Immunol       Date:  2017-08-28       Impact factor: 5.422

Review 5.  Systemic lupus erythematosus biomarkers: the challenging quest.

Authors:  Cristina Arriens; Jonathan D Wren; Melissa E Munroe; Chandra Mohan
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

6.  IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice.

Authors:  Caroline G McPhee; Jason A Bubier; Thomas J Sproule; Giljun Park; Martin P Steinbuck; William H Schott; Gregory J Christianson; Herbert C Morse; Derry C Roopenian
Journal:  J Immunol       Date:  2013-09-27       Impact factor: 5.422

7.  Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients.

Authors:  Hai-Feng Pan; Guo-Cui Wu; Yin-Guang Fan; Rui-Xue Leng; Hui Peng; Mo Zhou; Bao-Zhu Li; Yan Zhu; Jin-Hui Tao; Xiang-Pei Li; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2013-03-29       Impact factor: 2.631

Review 8.  IL-21 acts as a promising therapeutic target in systemic lupus erythematosus by regulating plasma cell differentiation.

Authors:  Xiao-Mei Deng; Shang-Xue Yan; Wei Wei
Journal:  Cell Mol Immunol       Date:  2014-08-04       Impact factor: 11.530

9.  STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus.

Authors:  Chuanlin Ding; Xingguo Chen; Paul Dascani; Xiaoling Hu; Roberto Bolli; Huang-Ge Zhang; Kenneth R Mcleish; Jun Yan
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

10.  Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.

Authors:  Shang-xue Yan; Xiao-mei Deng; Qing-tong Wang; Xiao-jing Sun; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-10-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.